OncLive and Targeted Oncology: Drug yields long-lasting benefits to treat PEComa tumors
OncLive and Targeted Oncology covered research presented by the University of Cincinnati's Thomas Herzog that found patients with perivascular epithelioid sarcoma (PEComa) of gynecologic or peritoneal origin experienced rapid, durable responses when treated with the drug nab-sirolimus.
At the 2024 SGO Annual Meeting on Women's Cancer, Herzog presented results from a subgroup analysis of the phase 2 AMPECT trial. Nab-sirolimus is the first and only FDA-approved treatment for advanced PEComa.
"The median time to response was extremely fast, about 1.4 months, and the duration of response was a little over 36 months," Herzog, MD, a University of Cincinnati Cancer Center member, the Paul and Carolyn Flory Professor in Gynecologic Oncology in the UC College of Medicine and director of UC Health’s Gynecologic Cancer Disease Center, told Targeted Oncology. "It is important to remember these responses occur often rapidly, and they are quite durable."
Watch the Targeted Oncology video.
Featured photo at top of Thomas Herzog. Photo provided.
Related Stories
Pocket-sized population threat
May 18, 2026
The Financial Times took a deep dive into why populations around the world continue to be on the decline. The publication cited new University of Cincinnati research as part of the investigation that looks at the fall of fertility in the digital era.
UC finds integrating substance use disorder treatment into clinic-based internal medicine expands access to care
May 18, 2026
A University of Cincinnati primary care teaching clinic integrates substance use disorder treatment into resident training, expanding access to addiction care and boosting physician confidence.
A jolly good trip: Bearcats take on London for fragrance company
May 18, 2026
Six NEXT Innovation Scholars at the University of Cincinnati traveled to London to transform field research into actionable recommendations for British luxury bath, body and fragrance brand Molton Brown.